The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Cytokine effects on the basal ganglia and dopamine function: The subcortical source of inflammatory malaise
Open accessAbstract
Data suggest that cytokines released during the inflammatory response target subcortical structures including the basal ganglia as well as dopamine function to acutely induce behavioral changes that support fighting infection and wound healing. However, chronic inflammation and exposure to inflammatory cytokines appears to lead to persisting alterations in the basal ganglia and dopamine function reflected by anhedonia, fatigue, and psychomotor slowing. Moreover, reduced neural responses to hedonic reward, decreased dopamine metabolites in the cerebrospinal fluid and increased presynaptic dopamine uptake and decreased turnover have been described. This multiplicity of changes in the basal ganglia and dopamine function suggest fundamental effects of inflammatory cytokines on dopamine synthesis, packaging, release and/or reuptake, which may sabotage and circumvent the efficacy of current treatment approaches. Thus, examination of the mechanisms by which cytokines alter the basal ganglia and dopamine function will yield novel insights into the treatment of cytokine-induced behavioral changes and inflammatory malaise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–224 of 224
Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds
Pucchio, T. D., Danese, S., CRISTOFARO, R. D., & Rutella, S. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903512974 · Cited by 41
Sissolak, G., Hoffbrand, A. V., Mehta, A. B., & GANESHAGURU, K. (1992) · PubMed · Cited by 41
Theodore, S., Cass, W. A., & Maragos, W. F. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.009 · Cited by 40
Effect of interferon-α on tyrosine hydroxylase and catecholamine levels in the brain of rats
Kumai, T., Tateishi, T., Tanaka, M., WATANABÉ, M., Shimizu, H., & Kobayashi, S. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00660-3 · Cited by 40
Observational studies of dopamine D1 and D2 agonists in squirrel monkeys
Rosenzweig-Lipson, S. J., Hesterberg, P. E., & Bergman, J. (1994) · Psychopharmacology · doi:10.1007/bf02244865 · Cited by 39
Sleep EEG in depressed and nondepressed patients with Parkinson's disease
Kostić, V., Susic, V., Przedborski, S., & Šternić, N. (1991) · Journal of Neuropsychiatry · doi:10.1176/jnp.3.2.176 · Cited by 33
Reyes, T. M., & Coe, C. L. (1996) · Journal of Neuroimmunology · doi:10.1016/0165-5728(96)00038-0 · Cited by 31
Administration of pegylated interferon-α-2a or -2b does not induce sickness behavior in Lewis rats
Loftis, J. M., Wall, J. M., Pagel, R. L., & Hauser, P. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.07.006 · Cited by 29
Sunami, M., Nishikawa, T., Yorogi, A., & Shimoda, M. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00012 · Cited by 29
Nadjar, A., Combe, C., Busquet, P., Dantzer, R., & Parnet, P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.04.035 · Cited by 27
Belevych, N., Buchanan, K., Chen, Q., Bailey, M. T., & Quan, N. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.05.007 · Cited by 27
Recovery after l-DOPA treatment in peginterferon and ribavirin induced parkinsonism
Bersano, A., Aghemo, A., Rumi, M. G., Ballabio, E., Candelise, L., & Colombo, M. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.10.003 · Cited by 26
Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-α
Ho, B. T., Huo, Y.-Y., Lu, J., Tansey, L. W., & Levin, V. A. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90446-m · Cited by 26
Wang, J., Zeng, X., Fan, G.-X., Yuan, Y., & Tang, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.12.046 · Cited by 26
Hashimoto, R., Nagatsu, T., Ohta, T., Mizutani, M., & Omura, I. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.047 · Cited by 26
Sato, T., Suzuki, E., Yokoyama, M., Semba, J., Watanabe, S., & Miyaoka, H. (2006) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2006.01538.x · Cited by 24
Visualizing the evolution of abnormal metabolic networks in the brain using PET
Spetsieris, P. G., Moeller, J. R., Dhawan, V., Ishikawa, T., & Eidelberg, D. (1995) · Computerized Medical Imaging and Graphics · doi:10.1016/0895-6111(95)00011-e · Cited by 23
Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
Sarasombath, P., Sumida, K. N. M., & Kaku, D. A. (2002) · PubMed · Cited by 23
Spencer, T. J., Madras, B. K., Bonab, A. A., Dougherty, D. D., Clarke, A., Mirto, T., Martin, J., & Fischman, A. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.026 · Cited by 21
[Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C].
Mizoi, Y., Kaneko, H., Oharazawa, A., & Kuroiwa, H. (1997) · PubMed · Cited by 21
Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.
Donnelly, S. (1998) · PubMed · Cited by 20
Can rodents be used to model interferon-α-induced depressive symptoms?
Loftis, J. M., Hauser, P., Macey, T. A., & Lowe, J. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.004 · Cited by 16
Candito, M., Nagatsu, T., Chambon, P., & Chatel, M. (1994) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(94)80070-7 · Cited by 14
Effect of in vivo striatal perfusion of lipopolysaccharide on dopamine metabolites
Mauriño, R., Machado, A., & Santiago, M. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.050 · Cited by 14
Cited by
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Self-citationNeuroscience of apathy and anhedonia: a transdiagnostic approach
Husain, M., & Roiser, J. P. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0029-9 · Cited by 640
Felger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung, M. Y., Hu, X., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.168 · Cited by 620
Self-citationInflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Self-citationImaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
Self-citation
Metadata
- Authors
- Felger, J. C., & Miller, A. H.
- Venue
- Frontiers in Neuroendocrinology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 33
- Issue
- 3
- Pages
- 315-327
- ISSN
- 0091-3022 (ISSN-L)
- OpenAlex
- W2069604660
- Cited by
- 391
- References
- 224
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.